BridGene Biosciences
PrivateLast Round
Series B
Extension
Oct 16, 2025
Total Funding Raised
$79.02M
Company Overview
BridGene Biosciences operates in Healthcare & Life Sciences and is based in San Jose, California. Its latest recorded funding round was a Series B Extension round in October 2025.
BridGene Biosciences is a biotechnology company that develops therapeutics for traditionally untreatable targets by leveraging advanced technologies such as covalent chemistry, chemical proteomics, and quantitative mass spectrometry.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BridGene Biosciences Comparables
Compare BridGene Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Totus Medicines | 88% | |
| Frontier Medicines | 87% | |
| Belharra Therapeutics | 86% |
For institutional investors. Book with your work email.
BridGene Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Oct 16, 2025 | ||||
| Series B | Jul 27, 2022 | ||||
| Series A | May 5, 2021 | ||||
| Grant | Sep 18, 2020 | ||||
| Grant | Sep 15, 2018 |
For institutional investors. Book with your work email.
BridGene Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series B |
| National Cancer Institute | Grant |
| Kaitai Capital | Series A |
| NIH RADx | Grant |
| Junson Capital | Series B |
| Lapam Capital | Series B Extension, Series B |
| Grains Valley Venture Capital | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 5, 2026
Nobel laureate Bruce A. Beutler, M.D. joins the board.
- Oct 23, 2025
Presenting three posters at the 2025 AACR-NCI-EORTC International Conference.
For institutional investors. Book with your work email.
BridGene Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BridGene Biosciences's valuation, stock price, and market status.
Is BridGene Biosciences a public or private company?
BridGene Biosciences is a private company.
What is the current stock price of BridGene Biosciences?
BridGene Biosciences is a private company, so its shares have no public market price. Caplight tracks BridGene Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BridGene Biosciences worth (valuation)?
Valuation information for BridGene Biosciences is not publicly available.
Can I buy BridGene Biosciences stock?
BridGene Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BridGene Biosciences's last funding round?
BridGene Biosciences's most recent funding round was Series B Extension on October 16, 2025.
Who are the main investors in BridGene Biosciences?
Key investors in BridGene Biosciences include Kaitai Capital, Junson Capital, Wedo Venture Partners, Bayland Capital.
Will BridGene Biosciences IPO soon?
No public IPO plans have been announced for BridGene Biosciences.
How can I track BridGene Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in BridGene Biosciences's shares on secondary markets.